Halozyme Options Stretch to May 2027, 234 Days Out

New options contracts on Halozyme Therapeutics Inc (Symbol: HALO) began trading on Sept. 29, 2026 for the May 2027 expiration, 234 days from the open, with the shares changing hands at 111.36, down 1.36% on the day as of 15:20 GMT.

Options traders in Halozyme Therapeutics Inc (Symbol: HALO) got a new calendar slot on Tuesday. Contracts for the May 2027 expiration began trading, giving buyers and sellers a series that sits 234 days out from the session in which it opened. The underlying shares were changing hands at 111.36, down 1.36% on the day, as of the last trade at 15:20:48 GMT on Sept. 29, 2026.

That is the whole of the event, and it is a routine one: exchanges roll new long-dated expirations into the chain as older ones approach their final weeks. But routine does not mean irrelevant. A new far-dated series changes what is possible for anyone who wants to express a view on a single biotech name over a horizon measured in seasons rather than weeks.

What 234 Days of Time Value Actually Buys

An option's price has two components. The first is intrinsic value, the amount by which a strike is already in the money against the current share price. The second is time value, the premium a buyer pays for the possibility that the stock moves further in their favour before the contract expires. Time value is the part that decays, and it is the part that the calendar governs.

With 234 days to run, the May 2027 Halozyme series carries roughly 33 weeks of that optionality, on an illustrative basis from the stated day count. For a buyer, that is a long runway: more scheduled corporate events, more data, more opportunity for a thesis to play out before the clock runs down. For a seller, the same 234 days is the reason the premium collected is larger than on a near-dated contract, and also the reason the obligation is harder to manage. Long-dated premium looks generous on day one and then sits on the book for the better part of a year.

The Nasdaq Markets listing notes exactly that point: time value is one of the key inputs into what an option buyer is willing to pay, which is why the opening of a new far expiration is treated as news in the options community at all.

The Share Price the New Series Is Priced Against

Every strike in the new chain is measured against a live share price, and Tuesday's tape for Halozyme was mildly negative. The stock closed the prior session at 112.89 and was quoted at 111.36 at the time of the last trade — a decline of 1.53 points on the day, derived from those two figures. The intraday band ran from 111.05 to 114.52, a spread of 3.47 points from low to high, meaning the stock had already covered real ground in both directions before settling toward the lower end of its range.

That matters for anyone sizing a position in the new series. A stock that swings through a three-point-plus band in a single session is one where implied volatility — the market's forward estimate of how much a share will move, embedded in option premiums — is not going to be cheap. Long-dated contracts on a volatile single name tend to carry chunky premiums, which is attractive to sellers and expensive for buyers.

How Tuesday's Move Sits Against the Broad Market

Halozyme's decline came on a day when the major benchmarks were split rather than uniformly weak. The S&P 500 proxy SPY was at $763.32, off 0.30% from a prior close of $765.61 and hugging the bottom of its $763.27–$766.98 range. The Dow 30 tracker DIA was the weakest of the three at $510.99, down 0.59%. The Nasdaq 100 proxy QQQ bucked the pattern, up 0.10% at $737.27 against a prior close of $736.53.

So the tape was not broadly risk-off, and large-cap technology was holding up. Halozyme's 1.36% slide was steeper than the drop in either the S&P 500 or the Dow proxy, and it ran against a modestly higher Nasdaq 100. Single-name biotech moves frequently have little to do with index direction, and nothing in the available data ties Tuesday's dip to a company-specific catalyst. The reasonable read is that this was idiosyncratic drift within an unremarkable session, not a sector repricing.

Who Uses a New Far-Dated Expiration, and For What

Three groups typically reach for a newly opened long expiration.

• Covered-call writers. Holders of the stock who sell upside calls against their shares to generate income. A May 2027 strike lets them collect a larger single premium than a monthly contract, at the cost of capping their upside for the better part of two calendar years.
• Cash-secured put sellers. Investors willing to own Halozyme at a lower price, who sell puts below the market and take the premium for agreeing to buy if assigned. The new series extends how far out that commitment can be written.
• Directional buyers and hedgers. Anyone whose view on the company depends on events that have not happened yet, and who does not want a near-dated contract expiring before the thesis has a chance to resolve.

Long-dated options come with trade-offs that near-dated ones do not. Open interest in a freshly listed expiration starts at nothing, so bid-ask spreads are typically wide until activity builds. Getting out early can cost more than getting in. And capital committed to a 234-day position is capital that is not available elsewhere for that period.

What to Watch From Here

The practical next step for traders is the chain itself: which strikes get listed, where the bids and offers settle, and whether open interest accumulates at particular levels. Concentration at a given strike is often a useful tell about where larger holders see either a ceiling worth selling or a floor worth defending.

Beyond that, the variables that will drive the value of these contracts are the ordinary ones for a commercial-stage biotech: revenue trajectory, licensing and royalty developments, and any regulatory or partnership news that lands between now and the May 2027 expiration. None of that is knowable from the option listing. What the listing does is give the market a longer instrument with which to take a position on it — and 234 days is a long time in this sector.

Key facts

• Ticker and last price: HALO — 111.36, down 1.36% as of 15:20:48 GMT, Sept. 29, 2026
• New expiration: May 2027 contracts began trading Sept. 29, 2026
• Days to expiration: 234 days from the opening session
• Intraday range: 111.05 to 114.52; prior close 112.89

Frequently asked questions

What happened with Halozyme options on Sept. 29, 2026?

New options contracts on Halozyme Therapeutics Inc (Symbol: HALO) began trading for the May 2027 expiration. The series opened with 234 days remaining until expiry. This is a routine exchange action that extends the available option calendar further out, giving traders a longer-dated instrument for the stock.

Why does the number of days to expiration matter?

An option's premium includes time value — what a buyer pays for the chance the stock moves in their favour before expiry. More days means more of that optionality and a higher premium, all else equal. With 234 days, the May 2027 Halozyme series carries substantially more time value than a near-dated monthly contract.

Where was Halozyme stock trading when the new series opened?

Halozyme was quoted at 111.36 as of the last trade at 15:20:48 GMT on Sept. 29, 2026, down 1.36% on the day from a prior close of 112.89. The stock traded between 111.05 and 114.52 during the session, ending the observed period near the lower end of that band.

How did the broader market perform that day?

The session was mixed. The S&P 500 proxy SPY was at $763.32, down 0.30%, and the Dow 30 tracker DIA was at $510.99, down 0.59%. The Nasdaq 100 proxy QQQ rose 0.10% to $737.27. Halozyme's decline was steeper than either falling benchmark.

What are the risks of trading long-dated options?

Newly listed far expirations start with no open interest, so bid-ask spreads are often wide and exiting early can be costly. Capital is tied up for the full period. Sellers collect larger premiums but carry obligations for many months, and covered-call writers cap upside over that entire horizon.

Does a new options expiration say anything about the company's outlook?

No. Exchanges add long-dated expirations on a schedule as existing series approach expiry. The listing reflects the options calendar, not any view on Halozyme's business, pipeline or financial results. Any move in the shares on the same day is unrelated to the contracts being opened.

Sources

• HALO May 2027 Options Begin Trading — Nasdaq Markets

Photo: sergeitokmakov · Pixabay Content License — source